Information  X 
Enter a valid email address

Company Name matching 'Sanofi'

Date
Time Source
Company
Announcement
07 May 2019 2:00 pm GNW     Sanofi Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
30 Apr 2019 5:00 pm GNW     Sanofi Sanofi: Annual General Meeting of April 30, 2019
27 Apr 2019 12:20 am GNW     Sanofi Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
26 Apr 2019 9:00 pm GNW     Sanofi ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
  4:15 pm GNW     Sanofi CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
  6:30 am GNW     Sanofi Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
08 Apr 2019 6:01 am GNW     Sanofi Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
22 Mar 2019 6:15 pm GNW     Sanofi Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
15 Mar 2019 8:01 pm GNW     Sanofi Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
08 Mar 2019 7:49 pm GNW     Sanofi Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
  6:00 am GNW     Sanofi Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
01 Mar 2019 1:13 pm GNW     Sanofi Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
25 Feb 2019 5:45 pm GNW     Sanofi Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
12 Feb 2019 6:01 am GNW     Sanofi Sanofi appoints Ameet Nathwani Chief Digital Officer
07 Feb 2019 6:30 am GNW     Sanofi Sanofi delivers 2018 business EPS growth of 5.1% at CER
06 Feb 2019 9:00 pm GNW     Sanofi Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
  4:43 pm GNW     Sanofi Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
05 Feb 2019 6:01 am GNW     Sanofi Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
04 Feb 2019 6:00 am GNW     Sanofi Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
21 Jan 2019 5:32 pm GNW     Sanofi Pasteur Sanofi UK marketing authorisation granted for Sanofi Pasteur’s Trivalent Influenza Vaccine (Split Virion, Inactivated) High Dose?(TIV High Dose)
17 Jan 2019 11:19 pm GNW     Sanofi Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
07 Jan 2019 7:30 am GNW     Sanofi Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
19 Dec 2018 12:00 pm GNW     Sanofi Dengvaxia® vaccine approved for prevention of dengue in Europe
18 Dec 2018 9:30 pm GNW     Sanofi Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq
16 Nov 2018 12:00 pm GNW     Sanofi Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
11 Nov 2018 1:15 pm GNW     Sanofi Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
07 Nov 2018 10:05 pm GNW     Sanofi New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
06 Nov 2018 6:00 am GNW     Sanofi FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
01 Nov 2018 6:00 am GNW     Sanofi Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
31 Oct 2018 6:30 am GNW     Sanofi Sanofi Q3 2018 Performance Confirms Return to Growth
19 Oct 2018 10:58 pm GNW     Sanofi Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
  12:37 pm GNW     Sanofi Sanofi receives positive CHMP opinion for dengue vaccine
16 Oct 2018 6:00 am GNW     Sanofi Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
01 Oct 2018 6:00 am GNW     Sanofi Sanofi completes divestiture of Zentiva to Advent
28 Sep 2018 9:40 pm GNW     Sanofi Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
  9:31 pm GNW     Sanofi Sanofi: Availability of the Pre-quarterly Results Communication
15 Sep 2018 7:03 am GNW     Sanofi Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
13 Sep 2018 11:00 am GNW     Sanofi Sanofi to refocus two global business units
12 Sep 2018 6:00 am GNW     Sanofi FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
04 Sep 2018 5:15 pm GNW     Sanofi Sanofi reaches civil settlement with US SEC
03 Sep 2018 6:00 am GNW     Sanofi Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
31 Jul 2018 5:15 pm GNW     Sanofi Online Availability of Sanofi Group's Half-Year Financial Report for 2018
  6:55 am GNW     Sanofi Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
26 Jul 2018 6:01 am GNW     Sanofi Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st
29 Jun 2018 7:00 am GNW     Sanofi Sanofi: Availability of the Pre-quarterly Results Communication
  6:00 am GNW     Sanofi Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab)
28 Jun 2018 6:00 am GNW     Sanofi Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva
19 Jun 2018 6:44 am GNW     Sanofi Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer
  6:00 am GNW     Sanofi Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
13 Jun 2018 6:00 am GNW     Sanofi Sanofi : Sanofi successfully prices USD 2 billion bond issue
11 Jun 2018 6:00 am GNW     Sanofi Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan
04 Jun 2018 7:15 pm GNW     Sanofi Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
21 May 2018 7:15 pm GNW     Sanofi Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
16 May 2018 6:00 am GNW     Sanofi Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
14 May 2018 7:09 am GNW     Sanofi Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
  7:00 am GNW     Sanofi Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
02 May 2018 5:50 pm GNW     Sanofi Sanofi: Annual General Shareholders' Meeting of May 2, 2018
30 Apr 2018 6:01 am GNW     Sanofi Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
24 Apr 2018 6:30 am GNW     Sanofi Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1
17 Apr 2018 7:30 am GNW     Sanofi Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t